三生製藥(01530.HK):HER2創新藥“伊尼妥單抗”獲批上市 打破抗HER2單抗進口藥物壟斷局面
格隆匯6月19日丨三生製藥(01530.HK)宣佈,旗下三生國健自主研發的注射用伊尼妥單抗(商品名:賽普汀®)正式獲得國家藥品監督管理局(NMPA)批准,獲批的首個適應症為和化療聯合用於治療HER2陽性的轉移性乳腺癌。
作為國家863計劃、國家重大新藥創制項目及上海市重點科技攻關項目,國產創新抗HER2單抗伊尼妥單抗的獲批有望填補國內乳腺癌患者尚未滿足的臨牀治療需求,並將打破進口產品在抗HER2單抗市場的壟斷局面,提升民族創新藥可及性,惠及更多中國患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.